KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 8.44%.

  • Esperion Therapeutics' Return on Capital Employed rose 83400.0% to 8.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.44%, marking a year-over-year increase of 83400.0%. This contributed to the annual value of 1.9% for FY2024, which is 41100.0% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Return on Capital Employed of 8.44% as of Q3 2025, which was up 83400.0% from 0.96% recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Return on Capital Employed high stood at 8.44% for Q3 2025, and its period low was 2.71% during Q4 2023.
  • Its 5-year average for Return on Capital Employed is 0.39%, with a median of 0.86% in 2022.
  • In the last 5 years, Esperion Therapeutics' Return on Capital Employed crashed by -17600bps in 2023 and then surged by 83400bps in 2025.
  • Esperion Therapeutics' Return on Capital Employed (Quarter) stood at 0.99% in 2021, then rose by 3bps to 0.95% in 2022, then tumbled by -184bps to 2.71% in 2023, then surged by 124bps to 0.66% in 2024, then skyrocketed by 1184bps to 8.44% in 2025.
  • Its Return on Capital Employed was 8.44% in Q3 2025, compared to 0.96% in Q2 2025 and 0.63% in Q1 2025.